肠道微生态影响肝脏疾病的若干进展与思考*

doi:10.3969/j.issn.1672-5069.2020.06.002

Abstract

Chen Huiting, Zhou Yongjian. Highlights in intestinal microecology in patients with liver diseases[J]. Journal of Practical Hepatology, 2020, 23(6): 765-768.

[1] Marshall J C. The gut as a potential trigger of exercise-induced inflammatory responses. Can J Physiol Pharmacol, 1998,76(5):479-484.
[2] Philips C A, Augustine P, Yerol P K, et al. Modulating the intestinal microbiota: therapeutic opportunities in liver disease. J Clin Transl Hepatol, 2020,8(1):13-87.
[3] Adachi Y, Moore L E, Bradford B U, et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology, 1995,108(1):218-224.
[4] Cassard A, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol, 2018,24(2):100-107.
[5] Bajaj J S. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2019,16(4):235-246.
[6] Bajaj J S, Heuman D M, Hylemon P B, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol, 2014,60(5):940-947.
[7] Bajaj J S, Kakiyama G, Zhao D, et al. Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis. Alcohol Clin Exp Res, 2017,41(11):1857-1865.
[8] Leclercq S, Matamoros S, Cani P D, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A, 2014,111(42):E4485-E4493.
[9] Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology, 2015,148(1):203-214.
[10] Grander C, Adolph T E, Wieser V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut, 2018,67(5):891-901.
[11] Younossi Z M, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Transplantation, 2019,103(1):22-27.
[12] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009,49(6):1877-1887.
[13] Jiao N, Baker S S, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut, 2018,67(10):1881-1891.
[14] Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab, 2019,30(4):675-688.
[15] Engel B, Taubert R, Jaeckel E, et al. The future of autoimmune liver diseases-understanding pathogenesis and improving morbidity and mortality. Liver Int, 2020,40(S1):149-153.
[16] Terjung B, Sohne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human -tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut, 2009,59(6):808-816.
[17] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut, 2020,69(3):569-577.
[18] Lyu L, Fang D, Shi D, et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol, 2016,18(7):2272-2286.
[19] Ridlon J M, Kang D J, Hylemon P B, et al. Bile acids and the gut microbiome. Curr Opin Gastroenterol, 2014,30(3):332-338.
[20] Tamas T E P Z. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol, 2017,23(29):5412-5421.
[21] Kummen M, Holm K, Anmarkrud J A, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut, 2017,66(4):611-619.
[22] Rossen N G, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis, 2015,9(4):342-348.
[23] Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut, 2016,65(10):1681-1689.
[24] Torres J, Bao X, Goel A, et al. The features of mucosa-associated microbiota in primary sclerosing cholangitis. Aliment Pharmacol Ther, 2016,43(7):790-801.
[25] Chou H, Chien W, Wu L, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci U S A, 2015,112(7):2175-2180.
[26] Jun D W, Jun D W, Kim K T, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci, 2010,55(5):1465-1471.
[27] Lu H, Wu Z, Xu W, et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Microb Ecol, 2011,61(3):693-703.
[28] Wang J, Wang Y, Zhang X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients. Front Microbiol, 2017,8:2222.
[29] Wu Z, Lu H, Wu J, et al. Assessment of the fecal Lactobacilli population in patients with hepatitis B virus-related decompensated cirrhosis and hepatitis B cirrhosis treated with liver transplant. Microb Ecol, 2011,63(4):929-937.
[30] Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol, 2013,13(1):175.
[31] Inoue T, Nakayama J, Moriya K, et al. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis, 2018,67(6):869-877.
[32] Aly A M, Adel A, El-Gendy A O, et al. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog, 2016,8(1):42.
[33] Wang Y, Pan C Q, Xing H. Advances in gut microbiota of viral hepatitis cirrhosis. Biomed Res Int, 2019,2019:1-9.
[34] Acharya C, Bajaj J S. Altered microbiome in patients with cirrhosis and complications. Clin Gastroenterol Hepatol, 2019,17(2):307-321.
[35] Ahluwalia V, Betrapally N S, Hylemon P B, et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci Rep, 2016,6(1):26800.
[36] Bajaj J S, Ridlon J M, Hylemon P B, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol, 2012,302(1):G168-G175.
[37] Bravo J A, Forsythe P, Chew M V, et al. Ingestion of lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A, 2011,108(38):16050-16055.
[38] Dapito D H, Mencin A, Gwak G, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer cell, 2012,21(4):504-516.
[39] Wang L, Zhu R, Huang Z, et al. Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci, 2013,58(8):2223-2236.
[40] Loo T M, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE 2-mediated suppression of antitumor immunity. Cancer Discov, 2017,7(5):522-538.
[41] Schramm C. Bile acids, the microbiome, immunity, and liver tumors. N Engl J Med, 2018,379(9):888-890.
[42] Cho E J, Leem S, Kim S A, et al. Circulating microbiota-based metagenomic signature for detection of hepatocellular Carcinoma. Sci Rep, 2019,9(1):7536-7538.
[43] Han S H, Suk K T, Kim D J, et al. Effects of probiotics (cultured Lactobacillus subtilis/streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol, 2015,27(11):1300-1306.
[44] Philips C A, Phadke N, Ganesan K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol, 2018,37(3):215-225.
[45] Loman B R, Hernández-Saavedra D, An R, et al. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev, 2018,76(11):822-839.
[46] Esposito E, Iacono A, Bianco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr, 2009,139(5):905.
[47] Cao Q, Yu C, Yang S, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. HBPD INT, 2018,17(1):9-16.
[48] Stadlbauer V, Mookerjee R P, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol, 2008,48(6):945-951.
[49] Ren Y, Ye Z, Yang L, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology, 2017,65(5):1765-1768.
[50] Bajaj J S, Salzman N H, Acharya C, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology, 2019,70(5):1690-1703.

Highlights in intestinal microecology in patients with liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xia Shujing, Zhang Lili, Zhang Xiumei, et al. Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 43-46.
[2]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[3]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[4]	Li Pingying, Li Juan, Xie Shouzhen, et al. Clinical application of FibroTouchand abdominal color ultrasound and computed tomography in diagnosis of individuals with nonalcoholic fatty liver disease in plateau regions [J]. Journal of Practical Hepatology, 2020, 23(6): 817-820.
[5]	Zhang Jianrong, Gu Erli, Wang Zhongcheng, et al. Comparison of clinical characteristics of patients with autoimmune hepatitis, primary biliary cholangitis and AIH/PBC overlap syndrome [J]. Journal of Practical Hepatology, 2020, 23(6): 829-832.
[6]	Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD [J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.
[7]	Fang Yi, Chen Yixiong, Pei Dongping, et al.. Short-term efficacy of entecavir and lactobacillus acidophilus compound combination in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(5): 634-637.
[8]	Kong Ming, Duan Zhongping, Chen Yu. Focus on nutrition in patients with chronic liver disease [J]. Journal of Practical Hepatology, 2020, 23(4): 459-461.
[9]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.
[10]	Tang Xiaofei, Zhong Mengju, Shen Haijuan. Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats [J]. Journal of Practical Hepatology, 2020, 23(3): 328-331.
[11]	Tang Xinya,Hou Sen,Jiao Yingying. Effect of captopril on steatosis of hepatocytes in rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(3): 332-335.
[12]	Shen Jingyong, Guo Xiangyun, Zhou Hui, et al. Effect of radical therapy forHelicobacter pylori on serum inflammatory factors and lipid metabolism in patients with Hp positive non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(3): 364-367.
[13]	Song Yu, Wang Fang. Efficacy of transhepatic artery autologous bone marrow stem cell transplantation in the treatment of patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2020, 23(3): 388-391.
[14]	Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.
[15]	Huang Jucun, Hu Donghui, Zhang Jianjun, et al. Protection of liver injuries by lentivirus-transfected miR-203 overexpression in rats with alcohol-induced liver disease [J]. Journal of Practical Hepatology, 2020, 23(2): 171-174.